Sale!

Oncomine Chronic Myeloid Leukemia CML Panel Test

8,190 د.إ

-10%

The Oncomine Chronic Myeloid Leukemia (CML) Panel Test is a comprehensive genomic profiling assay designed specifically for the analysis of genes associated with Chronic Myeloid Leukemia. This cutting-edge test, available at DNA Labs UAE, leverages next-generation sequencing (NGS) technology to identify key genetic mutations and variations in the DNA of patients diagnosed with CML. By analyzing a targeted panel of genes known to be implicated in the pathogenesis and progression of CML, the test provides critical insights that can guide personalized treatment strategies and decision-making.

With a cost of 8190 AED, the Oncomine CML Panel Test represents a significant investment in the precision medicine approach to cancer care. It enables healthcare providers to tailor treatments based on the specific genetic makeup of an individual’s cancer, potentially improving outcomes and minimizing unnecessary side effects. This test is particularly valuable for identifying resistance mutations that may affect the response to tyrosine kinase inhibitors, a common treatment for CML, thereby assisting clinicians in selecting the most effective therapy for their patients.

Performed at DNA Labs UAE, a facility renowned for its state-of-the-art genetic testing services, the Oncomine CML Panel Test is conducted under stringent quality controls to ensure accurate and reliable results. Patients undergoing this test can expect a thorough analysis of their condition, contributing to a more informed and personalized approach to their treatment plan.

Home  Sample collection service available

  • 100% accuaret Test Results
  • Ranked as Most trusted Genetic DNA Lab
  • This test is not intended for medical diagnosis or treatment
Guaranteed Safe Checkout

ONCOMINE CHRONIC MYELOID LEUKAEMIA CML PANEL Test

At DNA Labs UAE, we offer the ONCOMINE CHRONIC MYELOID LEUKAEMIA (CML) PANEL Test, a comprehensive diagnostic tool using next-generation sequencing (NGS) technology to detect mutations in genes associated with CML.

Test Components

  • ABL1
  • ASXL1
  • CBL
  • DNMT3A
  • ETV6
  • HRAS
  • IDH1
  • IDH2
  • JAK2
  • KIT
  • KRAS
  • MYC
  • MECOM
  • NRAS
  • RUNX1
  • RB1
  • SF3B1
  • SH2B3
  • TP53
  • TET2
  • WT1

Fusion Genes

  • ABL1
  • ETV6
  • JAK2
  • KMT2A
  • MECOM
  • RUNX1

Test Cost

The cost of the ONCOMINE CHRONIC MYELOID LEUKAEMIA CML PANEL Test is AED 8190.0.

Sample Condition

For this test, we require a minimum of 2 mL whole blood or bone marrow sample in a lavender top (EDTA) tube. The sample should be shipped refrigerated and should not be frozen. Please ensure that the NGS Test Requisition Form is duly filled.

Report Delivery

The sample should be submitted by the 1st or 16th of every month, and the report will be delivered on the 15th or 30th of the same month.

Method

The ONCOMINE CHRONIC MYELOID LEUKAEMIA CML PANEL Test is performed using next-generation sequencing (NGS) technology.

Test Type

This test is specifically designed for the diagnosis of leukemia, particularly chronic myeloid leukemia (CML).

Doctor

This test is recommended to be performed by a hematologist or oncologist.

Test Department

This test is conducted in our Molecular Diagnostics department.

Pre Test Information

It is mandatory to fill the NGS Test Requisition Form before undergoing the ONCOMINE CHRONIC MYELOID LEUKAEMIA CML PANEL Test.

Test Details

The ONCOMINE CHRONIC MYELOID LEUKAEMIA (CML) PANEL Test is a highly accurate and minimally invasive diagnostic tool that provides a comprehensive view of the genetic landscape of a patient’s CML. It detects mutations in 27 genes commonly associated with CML, including BCR-ABL1, JAK2, and TP53.

This test enables clinicians to make more personalized treatment decisions, monitor disease progression, and detect the emergence of new mutations that may impact treatment efficacy. Results are typically available within a few days, allowing for timely intervention and improved patient outcomes in the management of CML.

Test Name ONCOMINE CHRONIC MYELOID LEUKAEMIA CML PANEL Test
Components ABL1, ASXL1, CBL, DNMT3A, ETV6, HRAS, IDH1,IDH2, JAK2, KIT, KRAS,MYC, MECOM, NRAS, RUNX1, RB1, SF3B1, SH2B3, TP53, TET2, WT1 FUSION GENE – ABL1, ETV6, JAK2, KMT2A, MECOM, RUNX1
Price 8190.0 AED
Sample Condition 3 mL (2 mL min.) whole Blood OR Bone Marrow in 1 Lavender top (EDTA) tube. Ship refrigerated. DO NOT FREEZE. Duly filled NGS Test Requisition Formis mandatory.
Report Delivery Sample by 1st / 16th of every month; Report 15th / 30th of Same month
Method NGS
Test type Leukemia
Doctor Hematologist, Oncologist
Test Department: MOLECULAR DIAGNOSTICS
Pre Test Information Duly filled NGS Test Requisition Formis mandatory.
Test Details

The Oncomine Chronic Myeloid Leukaemia (CML) Panel Test is a diagnostic tool that uses next-generation sequencing (NGS) technology to detect mutations in genes associated with CML. The panel includes 27 genes that are commonly mutated in CML, including BCR-ABL1, JAK2, and TP53.

The test is designed to provide clinicians with a comprehensive view of the genetic landscape of a patient’s CML, allowing for more personalized treatment decisions. It can also be used to monitor disease progression and detect the emergence of new mutations that may impact treatment efficacy.

The Oncomine CML Panel Test is performed on a small sample of blood or bone marrow, and results are typically available within a few days. It is a minimally invasive and highly accurate diagnostic tool that can help improve patient outcomes in the management of CML.